GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More
by Zacks Equity Research
Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $33.72, moving +0.6% from the previous trading session.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $33.59 in the latest trading session, marking a -1.29% move from the prior day.
Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.
Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?
by Zacks Equity Research
An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.
Glaxo (GSK) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $34.58, marking a +0.93% move from the previous day.
The Zacks Analyst Blog Highlights Apple, Linde, Marsh & McLennan Companies, GSK and Expedia
by Zacks Equity Research
Apple, Linde, Marsh & McLennan Companies, GSK and Expedia are included in this Analyst Blog.
Top Analyst Reports for Apple, Linde & Marsh & McLennan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Marsh & McLennan Companies, Inc. (MMC).
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
Gilead (GILD) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy
by Zacks Equity Research
Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology
by Zacks Equity Research
Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
by Zacks Equity Research
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
by Zacks Equity Research
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
GSK (GSK) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag
by Zacks Equity Research
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
GSK Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $35.17, moving +1.35% from the previous trading session.
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?
by Zacks Equity Research
Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.